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ABSTRACT
Successful treatment of prosthetic joint infections often requires multiple surgical interventions and
prolonged antimicrobial therapy. However, in certain situations, a surgical approach may not be in the
best interest of the patient. A conservative approach was used to treat 34 patients with prosthetic joint
infection between 1995 and 2003. Diagnosis of infection was based on clinical–microbiological evidence,
confirmed by 99Tc-labelled leukocyte scintigraphy, and involved 12 Staphylococcus aureus infections, nine
Staphylococcus epidermidis infections, two Enterococcus faecalis infections, two mixed infections (S. aureus
plus Pseudomonas aeruginosa; S. epidermidis plus E. faecalis), with the infecting pathogen being
unidentified for nine patients. Most infections were treated initially with intravenous or intramuscular
teicoplanin ± ciprofloxacin or rifampicin, followed by oral ciprofloxacin or minocycline plus rifampicin.
The mean duration of antimicrobial therapy was 41.2 weeks. Overall, only three patients did not
respond to therapy, and infection was controlled in the remaining 31 patients. Among these, no relapse
was observed in 17 patients during follow-up for 9–57 months; improvement with early (within
6 months of antibiotic discontinuation) or late relapse was observed in seven and three patients,
respectively; two patients improved clinically, but continued to receive antibiotic therapy; and two
patients whose condition improved initially were lost after a 6-month follow-up following discontinu-
ation of antibiotics. No patient complained of side effects requiring discontinuation of antibiotic therapy.
The study confirmed that suppression of infection, with salvage of the infected device in an acceptably
functional state, can be achieved in selected cases.
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INTRODUCTION
Infection rates following prosthetic joint implan-
tations occur at a frequency of 0.5–2% [1].
Staphylococcus aureus and coagulase-negative
staphylococci account for 45–55% of such infections,
regardless of the type of implant [1]. Successful
treatment of these infections is difficult, and
usually requires multiple surgical interventions
(removal of the device, one- or two-stage
reimplantation of a new device) and prolonged
antimicrobial therapy to achieve microbial sterili-
sation and a satisfactory functional result [1].
However, the patient may not always consent to
further surgery, or contraindications may exist,
including the patient’s clinical status, non-accept-
able functional results after removal of the pros-
thesis, or a well-fixed prosthesis that is difficult to
remove [2,3]. It has been suggested that a conser-
vative approach to certain prosthetic joint infec-
tions could be an appropriate option if adequate
surgical debridement is combined with prolonged
pathogen-targeted therapy [2–8]. To determine
the efficacy of such a therapeutic strategy, the
present study reviewed retrospectively the
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clinical–microbiological features and response to
therapy of 34 patients with prosthesis infection
who were treated in our institution over an 8-year
period.
PATIENTS AND METHODS
Thirty-four consecutive patients with prosthetic joint infections
(24 total hip prosthesis replacements; ten total knee prosthesis
replacements) who had received antimicrobial therapy in the
outpatient clinic between 1995 and 2003 were reviewed
retrospectively. Each patient was followed from the first visit
through all treatment and follow-up by one investigator (MV).
All patients included in the study had clinical, laboratory and
radiological evidence of orthopaedic implant infection. In
particular, the diagnosis of joint prosthesis infection was based
on the presence of at least one of the following: (1) hip or knee
prosthesis fistula; (2) inflammation in the area around the joint
and biological inflammatory syndrome; (3) hip or knee
prosthesis pain and biological inflammatory syndrome; or (4)
joint swelling and inflammatory syndrome. Biological inflam-
matory syndrome included an erythrocyte sedimentation rate
(ESR) of > 50 mm ⁄h and elevated levels of C-reactive protein
(CRP). For the purpose of this study, loosening of the joint,
identified radiographically, was not a diagnostic criterion,
since only patients with stable prostheses could be enrolled for
conservative medical treatment. Initial patient evaluation
always included 99Tc-labelled leukocyte scintigraphy to cor-
roborate the diagnosis of prosthesis infection and to evaluate
the extent of the infectious process.
Infectious episodes were defined as early, delayed or late
infections according to the appearance of signs and symptoms
of infection during the first 3 months, between 3 months and
2 years, or > 2 years following prosthesis implant, respectively
[7]. Early infections occurring within 4 weeks of surgery were
also recorded [7,8]. Microbiological studies were performed on
bone samples and sinus drainage, including direct microscopic
examination of leukocytes and bacteria, as well as aerobic and
anaerobic cultures. Bacteria were considered to be pathogens if
isolated at least twice from sinus drainage, or at least once
from fluid collected during deep needle aspiration or from an
intra-operative deep tissue specimen. Patients were checked
initially for blood cell count, liver and kidney function, and
ESR and CRP levels. Where indicated, extensive surgical
debridement was also combined with medical therapy.
Planned courses of antibiotic therapy, based on in-vitro
susceptibility data, were at least 6 months for hip prosthesis
infections and 9 months for knee prosthesis infections [2,4–6].
In circumstances where microbiological studies could not be
performed, or gave equivocal results (e.g., coagulase-negative
staphylococci from a single fistula discharge), empirical anti-
staphylococcal therapy was attempted. As a general approach,
after initiation of therapy, all patients were seen every
2–3 weeks for the first 3 months, then every 4–12 weeks for
6–24 months after antibiotic discontinuation, and finally every
6–12 months for a further 2 years.
Since, theoretically, microbial eradication of orthopaedic
device infections was not considered to be achievable [9,10],
improvement was assessed initially on the basis of disappear-
ance of clinical, biological and radiological evidence of
infection at the end of medical treatment, with no relapse
within the 6-month period following discontinuation of anti-
biotics [2,5]. Whenever possible, to corroborate evidence of
improvement, 99Tc-labelled leukocyte scintigraphy was per-
formed at the end of treatment and follow-up. Response to
therapy was eventually defined as follows: (1) improvement
with no apparent relapse after a 6-month follow-up; (2)
improvement with early relapse if the relapse occurred within
6 months of discontinuation of antibiotics; (3) improvement
with late relapse when the relapse occurred > 6 months
following discontinuation of antibiotics; (4) improvement with
no early relapse when improved patients were lost to follow-
up > 6 months following discontinuation of antibiotics; (5)
improvement with continued suppressive therapy when oral
antibiotics were continued for > 6 months (hip prosthesis) or
> 9 months (knee prosthesis) on the basis of minimal signs of
persisting infection on leukocyte scintigraphy despite a clear
clinical recovery, and ⁄or the patient’s refusal to discontinue
medical treatment; or (6) failure—no response to antibiotic
therapy.
Statistical analysis of the data was carried out with a two-
tailed chi-square or Fisher’s exact test, as appropriate.
RESULTS
Thirty-four cases of prosthetic joint infection were
included in the retrospective analysis. The demo-
graphic characteristics of the patients and details
of their response to therapy are shown in Table 1.
The infections involved 24 hip prostheses and ten
knee prostheses, with 12 early, 16 delayed and six
late infections. Potential host factors predisposing
to prosthesis infection [1] included nine (26.5%)
patients with a history of previous joint arthropl-
asty on the same joint, three (8.8%) patients with
diabetes, two (5.9%) patients receiving steroid
therapy, two (5.9%) patients with peri-operative
wound complications, one (2.9%) obese patient,
and 20 (58.8%) patients aged > 70 years. The
clinical presentation was variable, ranging from
acute septic arthritis, with the sudden onset of
joint pain, erythema, swelling and drainage at the
wound site, to a more frequent syndrome of
chronic and progressive pain, particularly with
motion or when bearing weight, functional
restriction and fistula with purulent secretion.
All the patients yielded initial positive results in
99Tc-labelled leukocyte scintigraphy.
Pathogens identified were methicillin-suscept-
ible Staphylococcus aureus (four infections),
methicillin-resistant S. aureus (MRSA) (eight infec-
tions), methicillin-susceptible Staphylococcus epider-
midis (four infections), methicillin-resistant
S. epidermidis (five infections), Enterococcus faecalis
(two infections), methicillin-resistant S. epidermidis
plus E. faecalis (one mixed infection), and MRSA
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Table 1. Characteristics of 34 cases of prosthetic joint infection
Case Age, sex
Risk
factors
Type of
prosthesis
Onset of
infection
Bacteria ⁄
diagnostic
procedure Debridement
Initial
treatment
(weeks)
Subsequent
oral
treatment
(weeks)
Total
treatment
duration
(weeks)
Follow-up
(months) Outcome
1 79, F AA Hip Delayed MRSA,
drainage
of sinuses
No cip (20) mh + rd (20) 40 19 INR ﬁ Surgery
for LAL after
9 months
2 50, F PWC Hip Early,
(within
1 month)
MRSE +
Enterococcus
faecalis,
deep
aspiration
Yes tec + cip + rd (16) amc + rd (10) 26 9 IER (relapsed
after
1 month) ﬁ
Surgery
3 73, F AA, PJS Hip Early MSSA,
deep
aspiration
No tec + rd + levo (12) levo + rd (12) 24 27 INR
4 48, F PJS Hip Early MSSE,
drainage
of sinuses
Yes tec + amc + rd (18) mh + rd (14) 32 40 INR ﬁ Surgery
for LAL after
18 months
5 60, F No Hip Delayed MSSA,
drainage
of sinuses
Yes cip + rd (24) No 24 – INER
6 55, M DM, PJS Hip Early MRSE,
intra-operative
culture
Yes tec + fos (20) cip + rd (4) 24 36 INR
7 75, F AA, PJS Hip Delayed Unknown No mh + rd (48) – 48 – Failure
8 65, F No Hip Delayed Unknown Yes amc + rd (14) mh + rd (14) 28 12 INR
9 79, F AA Hip Delayed MRSA +
Pseudomonas
aeruginosa,
drainage
of sinuses
No tec + cip (16),
tec + levo (12)
– 28 27 INR
10 78, F AA, PJS Hip Late MRSE,
drainage
of sinuses
No tec + rd (12) mh + rd (30) 42 27 ILR (relapsed
after
14 months) ﬁ
ICST (mh)
11 86, F AA Hip Early
(within
1 month)
Enterococcus
faecalis,
drainage
of sinuses
No amc (4) amc + levo (20),
amc (4)
28 – INER
12 78, F AA, PJS Hip Delayed MRSA,
drainage
of sinuses
No tec + cip + rd (8) mh + rd (24) 32 17 IER (relapsed
after
2 months) ﬁ
ICST (mh rd)
13 81, F AA Hip Delayed MRSA,
intra-operative
culture
Yes va, cld (4) mh (64) 68 10 ILR (relapsed
after
8 months) ﬁ
ICST (mh)
14 64, F DM Hip Late MSSE,
intra-operative
culture
Yes va, cld + levo (6) mh + rd (24),
mh (27)
57a – ICST (mh)
15 56, F O Hip Early MRSA,
drainage
of sinuses
Yes tec + cld (12),
tec + fos (12)
sxt + rd (16) 40 34 INR
16 67, F No Hip Delayed Unknown No cip + rd (38) – 38 57 INR
17 70, F AA, PJS,
PWC
Hip Late Unknown No tec (4) mh + rd (38) 42 15 IER (relapsed
after
2 months) ﬁ
Surgery
18 59, F PJS Hip Early
(within
1 month)
MRSA,
drainage
of sinuses
Yes va + rd + cip (12),
tec + levo (8)
mh + rd (4) 24 26 INR
19 67, F No Hip Delayed MRSA,
intra-operative
culture
Yes tec (24) mh + rd (20) 44 40 ILR (relapsed
after
12 months) ﬁ
ICST (mh)
20 77, F AA Hip Delayed MRSA,
drainage
of sinuses
No tec + rid (8) mh + rd (76) 84a – ICST (mh + rd)
21 74, F AA Hip Late Unknown No tec + cip (8) mh + rd (28) 36 9 INR
22 70, M AA, ST Hip Delayed MSSE,
intra-operative
culture
Yes tec + cip + rd (20)
cip + rd (4)
mh + rd (4) 28 11 IER(relapsed
after
5 months) ﬁ
ICST (mh)
23 72, M AA, PJS Hip Late MRSA,
deep
aspiration
Yes tec + moxi (12) mh + moxi (4),
cld (12)
28 17 IER (relapsed
after
4 months) ﬁ
ICST (mh)
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plus Pseudomonas aeruginosa (one mixed infec-
tion). Clinical specimens from which pathogens
were isolated are shown in Table 1. Blood cul-
tures were obtained from most cases of acute
onset infection, but no pathogens were isolated
from blood. The aetiology remained unknown in
the nine remaining cases, either because of neg-
ative cultures or patient refusal of invasive pro-
cedures (arthrocentesis, biopsy, etc.).
All patients received antibiotic therapy on an
outpatient basis, with three exceptions where
therapy was administered initially in hospital
(cases 13, 14 and 18). All patients began antimi-
crobial therapy within 3 months of the clinical
onset of infection. As shown in Table 1, most
patients underwent initial treatment with a gly-
copeptide, usually intramuscular teicoplanin
6 mg ⁄ kg ⁄day every 12 h for the first three to five
doses, then 6 mg ⁄ kg ⁄day every 24 h, either alone
or in combination with oral ciprofloxacin and ⁄ or
oral rifampicin (17 cases), or oral fosfomycin
3 g ⁄day (two cases). For patients with MRSA
and methicillin-resistant S. epidermidis infections,
oral minocycline 200 mg ⁄day, either alone or in
combination with rifampicin 600 mg ⁄day, was
the usual subsequent therapy. For methicillin-
susceptible S. aureus infections, a quinolone (usu-
ally oral ciprofloxacin 1.5 g ⁄day), either alone or
in combination with rifampicin or a b-lactam
(usually axetil cefuroxime 3 g ⁄day), was the usual
therapy. The mean total duration of antibiotic
therapy was 41.2 weeks (range 24–96 weeks). The
average duration of follow-up for the 29 cases
where antibiotics were, eventually, discontinued
was 22 months (range 9–57 months). Two
patients (cases 13 and 14) developed mild and
transient renal failure during initial therapy with
vancomycin; no other patient complained of
significant side effects requiring discontinuation
of antibiotic therapy.
Fig. 1 summarises the clinical outcomes in this
series of patients. Only three patients did not
Table 1. Continued.
Case Age, sex
Risk
factors
Type of
prosthesis
Onset of
infection
Bacteria ⁄
diagnostic
procedure Debridement
Initial
treatment
(weeks)
Subsequent
oral
treatment
(weeks)
Total
treatment
duration
(weeks)
Follow-up
(months) Outcome
24 63, F No Hip Delayed MRSE,
drainage
of sinuses
No cip (24) cld + levo (8) 30 12 INR
25 71, M AA Knee Early
(within
1 month)
MSSA,
intra-operative
culture
Yes tec + cip + rd (12),
tec + moxi + rd (12)
mh (12) 36 – Failure ﬁ
Surgery
26 81, F AA Knee Late Unknown No amc + rd (12) cld (4),
mh + rd (24)
40 9 INR
27 73, M AA Knee Early Unknown Yes amc + cn (36) amc (12) 48 43 INR ﬁ Surgery
for LAL after
13 months
28 65, F DM Knee Delayed MSSA,
drainage
of sinuses
No tec + cip + rd (8) cip + rd (20),
levo (16)
44 10 INR
29 73, M AA Knee Delayed MSSE,
drainage
of sinuses
No cip + a-cxm + rd (28),
tec + cip (8)
cip + rd (56) 92 31 IER (relapsed
after
5 months) ﬁ
Surgery
30 72, F AA Knee Early MRSE,
drainage
No tec + cip (4),
tec + levo (16)
mh + levo (20) 40 9 INR
31 75, M AA Knee Early
(within
1 month)
Enterococcus,
faecalis,
deep
aspiration
No amc + genta (4) amc + rd (48) 52 9 INR
32 60, F No Knee Early Unknown No tec (12) mh + rd (36) 36 20 INR
33 43, F ST Knee Delayed MRSE,
drainage
of sinuses
No tec + cip (24),
tec + rd (12)
mh + rd (24),
levo (24),
amc + rd (12)
96 – Failure ﬁ Surgery
Surgery
34 71, F AA Knee Delayed Unknown No mh + rd (8)
tec + cip (6)
mh + cip(16) 30 19 IER (relapsed
after
4 months) ﬁ
Surgery
levo, levofloxacin; cxm, cefuroxime; a-cxm, axetil-cefuroxime; rd, rifampicin; tec, teicoplanin; sxt, co-trimoxazole; fos, fosfomycin; mh, minocycline; cip, ciprofloxacin; va,
vancomycin; ma, cefamandole; ak, amikacin; cn, gentamicin; cld, clindamycin; amc, amoxycillin–clavulinic acid; moxi, moxifloxacin; INR, improvement with no relapse after
6 months following antibiotic discontinuation; IER, improvement with early relapse (within 6 months of antibiotic discontinuation); ILR, improvement with late relapse
(> 6 months following antibiotic discontinuation); INER, improvement with no early relapse (patients lost to follow-up after 6 months following antibiotic discontinuation);
ICST, improvement with continued suppressive therapy; LAL, late aseptic prosthesis loosening; ST, steroid therapy; AA, advanced age (> 70 years); DM, diabetes mellitus;
O, obesity; PWC, peri-operative wound complications; PJS, previous joint surgery; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus;
MRSE, methicillin-resistant Staphylococcus epidermidis; MSSE, methicillin-sensitive S. epidermidis.
aStill receiving oral treatment.
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respond to therapy, despite some initial signs of
clinical improvement. Eventually, two of these
patients underwent two-stage prosthesis replace-
ment (cases 25 and 33). The third patient (case 7)
had significant improvement, with pain reduction
and amelioration of the functional status of the
infected joint, but elevated ESR and CRP values
and positive 99Tc-labelled leukocyte scintigraphy
persisted. This patient refused surgery and is still
receiving chronic suppressive antibiotic therapy
with oral minocycline and rifampicin.
Two patients who improved (cases 5 and 11)
were lost to follow-up 6 months after discontinu-
ation of antibiotics; they were categorised as
improved with no early relapse, but could not
be evaluated for late relapse.
Improvement with no relapse was observed in
17 patients. Of these, three eventually under-
went surgery for late aseptic loosening, while
the remaining 14 patients are still undergoing
clinical observation (9–57 months).
Improvement with early relapse was observed
in seven patients. Of these, four (cases 2, 17, 29
and 34) underwent two-stage prosthesis replace-
ment and, eventually, were cured. The remaining
three patients improved further following contin-
ued suppressive therapy with oral minocycline,
either alone (cases 22 and 23) or in combination
with rifampicin (case 12), and are still undergoing
clinical observation (11–17 months).
Improvement with late relapse was observed in
three patients. Clinical symptoms (local pain,
fistula and positive 99Tc-labelled leukocyte
scintigraphy) and microbiological relapse (new
isolation of MRSA from fistula) was observed in
one patient with a hip prosthesis infection fol-
lowing discontinuation of antibiotics (case 19).
The remaining two patients (cases 10 and 13) had
clinical symptoms only (local pain with altered
ESR and CRP values and positive 99Tc-labelled
leukocyte scintigraphy). All three of these patients
eventually improved again with continued sup-
pressive therapy with oral minocycline.
Two patients improved, but continued to
receive suppressive antibiotic therapy. One of
these patients (case 20) refused to discontinue
antibiotics at the end of the planned period; the
other (case 14) was a high-risk diabetic patient
(female) with serious peripheral vascular disease
and polyneuropathy, for whom oral therapy with
minocycline was prescribed to avoid an infectious
relapse. As shown in Fig. 1, with the inclusion of
these two cases, eight patients were categorised as
improved with continued suppressive therapy.
Table 2 shows the relationship between early,
delayed and late appearance of prosthesis joint
infection and outcome. Overall, improvement
with no relapse was achieved in nine (75%) of
12 early infections vs. eight (36.3%) of 22 delayed
or late infections (p 0.03).
DISCUSSION
The conventional treatment for infected pros-
theses is still excision arthroplasty with a staged
revision, one- or two-stage reimplantation of a
new device, in conjunction with prolonged,
pathogen-targeted antibiotic treatment [1]. How-
ever, this therapeutic strategy may sometimes
require prolonged hospitalisation, while infected
patients are often elderly, with multiple co-
morbidities, who may suffer additional discom-
fort or serious peri-operative complications. For
these patients, and patients who cannot or will
not undergo further surgical interventions, pro-
longed antibiotic therapy in conjunction with
Failure
3
Surgery
2
Surgery
4
CST
1
CST
3
CST
3
ICST
8
Still
in follow-up
14
Surgery
(LAL)
3
IER
7
ILR
3
ICST
2
INER
2
INR
17
TOTAL PATIENTS
            (34)             
Fig. 1. Clinical outcome of conservative medical therapy
in 34 prosthetic joint infections. IER, improvement with
early relapse; ILR, improvement with late relapse; INR,
improvement with no relapse; INER, improvement with
no early relapse; ICST, improvement with continued
suppressive therapy (CST); LAL, late aseptic loosening.
Table 2. Relationship between early, delayed and late
appearance of prosthetic joint infection and improvement
with no relapse (INR)
Onset of infection
Number (%) of
cases with INR
a. Early (n = 12) 9 (75%)
b. Delayed (n = 16) 6 (37.5%)
c. Late (n = 6) 2 (33.3%)
a vs. b, p 0.04; a vs. b + c, p 0.03.
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surgical debridement, when necessary, seems a
reasonable alternative, despite only a few studies
regarding the efficacy of this therapeutic approach
[2,3,8,11].
In France, excellent cure rates were obtained for
staphylococcal orthopaedic infections with three
oral antibiotic regimens and a therapeutic strategy
similar to that adopted in the present study
[2,4–6]. Ofloxacin plus rifampicin cured 17
(81%) of 22 hip prosthesis infections and nine
(69%) of 15 knee prosthesis infections; in the
cured cases, seven hip prostheses and two knee
prostheses were not removed [5]. Fusidic acid
plus rifampicin cured 11 (52.3%) of 21 hip
prosthesis infections and eight (72.7%) of 11 knee
prosthesis infections; in only five of 19 cured cases
was device removal necessary [4]. Finally, cure
was achieved with high-dose oral co-trimoxazole
for eight (53.3%) of 15 prosthetic joint infections
(six hip prostheses and nine knee prostheses);
four (57%) of the seven failures were a result of
intolerance to the study drug or lack of compli-
ance with the therapeutic regimen [6]. Zimmerli
et al. [8] studied eight patients with a staphylo-
coccal prosthesis infection (five hip prostheses,
three knee prostheses) who presented within
28 days of implant, and obtained a 100% cure
rate without prosthesis removal with oral ciprofl-
oxacin plus rifampicin. However, these findings
cannot be compared to those of the present study,
in which only a minority (14.7%) of patients
presented with an infection within 1 month of the
prosthesis implant.
In previous studies [2,4–6,8], treatment efficacy
was evaluated after a post-treatment follow-up
period of 9–84 months. However, since a failure
rate of 69–77% with retention of the device has
been observed, relapse of an orthopaedic implant
infection treated by such conservative medical
therapy always remains possible [11–13]. More-
over, although there is a higher chance of relapse
within 6 months of the discontinuation of antibi-
otics, some studies [8,11] have observed relapse
after 1 year, as was seen for one patient in the
present series.
The present study adopted antibiotic regimens
that have either been used successfully for ‘long-
term outpatient antibiotic therapy’ of orthopaedic
implant infections or appeared promising in
in-vitro ⁄ in-vivo experimental models of foreign
body infection [1,8,14,15]. Rifampicin has been
used frequently, since this antibiotic retains
bactericidal activity against sessile staphylococci
adherent to implants and reaches high tissue and
intracellular concentrations [1,2,8]. When it is
used in combination with other active,
lipid-soluble agents, such as a quinolone or
minocycline, or with glycopeptides, emergence
of resistance to rifampicin can be prevented
[1,8,16–18]. Combinations of ofloxacin, ciprofloxa-
cin or pefloxacin plus rifampicin have been used
successfully for staphylococcal orthopaedic infec-
tions, caused usually by methicillin-susceptible
strains [1,4,8,17]. However, the combination of a
glycopeptide and a quinolone may prove synergic
in vitro against methicillin-resistant staphylococci,
and is more efficacious than glycopeptide mono-
therapy in in-vivo experimental models of
staphylococcal foreign body infection [17,19].
In the present series, infection was suppressed
in 31 (91.2%) of 34 patients, with no relapse being
observed in 17 (50%) patients after follow-up for
9–57 months following discontinuation of antibi-
otics. As observed previously [2,3,11], there was a
significantly better outcome for early compared to
delayed and delayed plus late infections (p 0.04
and p 0.03, respectively). Prolonged suppressive
antibiotic therapy was eventually adopted for
eight patients in order to treat or prevent early
and late relapses. As these infections are rarely
life-threatening, the pain-free, long-term function
of the device and the optimal tolerance of oral
antibiotics (usually minocycline ± rifampicin)
were the major criteria for prescribing continued
suppressive therapy [1,3,20].
The present study had some major limitations
relating to the retrospective nature of the analysis,
the fact that the patient population was not
homogeneous, and the wide ranges in duration
of therapy and follow-up. The apparently favour-
able results should therefore be considered with
caution as further, but not definitive, evidence
that medical therapy with prosthesis retention is
feasible in orthopaedic implant infections. As
outlined previously [2], in the absence of large,
randomised, prospective trials evaluating differ-
ent therapeutic strategies for the management of
orthopaedic device infection, solutions to the
controversial issues surrounding prosthetic joint
infection will be reached only by exploiting large
databases that lend themselves to rigorous statis-
tical analysis [2,7]. To this end, patients receiving
medical therapy while retaining the prosthesis,
and ⁄ or receiving long-term ambulatory antibiotic
836 Clinical Microbiology and Infection, Volume 10 Number 9, September 2004
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 10, 831–837
regimens, should be included in research proto-
cols defining: (1) strict criteria for diagnosis,
prognosis and cure of the prosthesis infection
[2]; (2) a scoring system for the clinical status [7];
and (3) specific antimicrobial treatment courses
according to the pathogen and prosthesis (e.g.,
knee vs. hip) involved [1,2,5,21,22].
Overall, the present data seem to confirm that
suppression of infection with salvage of the
infected device in an acceptably functional state
can be achieved in selected cases. In particular,
long-term outpatient antibiotic therapy may be a
feasible alternative option for patients with early
infection in which surgery may be contraindica-
ted (e.g., older patients with multiple co-morbi-
dities), patients for whom the post-surgical
functional result may be non-acceptable (e.g.,
patients with previous multiple joint surgery),
and patients who refuse surgery. Continued
suppressive antibiotic therapy may be required
for some patients who appear to be at higher risk
of relapse despite significant clinical improve-
ment. However, a conservative medical approach
requires strict clinical monitoring of its perform-
ance, of possible side effects, and of the patient’s
compliance with the therapeutic regimen. Finally,
prolonged follow-up after discontinuation of
antibiotics is necessary to assess whether a defin-
itive cure has been achieved.
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